The most recent investment, a Series B funding round on 08 January 2024, attracted substantial support from prominent investors including CICC Capital, Guizhou Zhongken Fund, and China Merchants Venture Capital. This investment signifies the confidence that key players in the investment landscape have in Lanmei Technology's potential for growth and disruption in the market.
Lanmei Technology has successfully positioned itself as a trailblazer in the intersection of agriculture, technology, and health care, and the recent investment round is a testament to the company's strong potential and the recognition it has garnered from notable investors.
GROUPE INVIVO
